Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Currently available drugs against Alzheimer's disease (AD) target cholinergic and glutamatergic neurotransmissions without affecting the underlying disease process. Putative disease-modifying drugs are in development and target β-amyloid (Aβ) peptide and tau protein, the principal neurophatological hallmarks of the disease. Areas covered: Phase III clinical studies of emerging anti-Aβ drugs for the treatment of AD were searched in US and EU clinical trial registries and in the medical literature until May 2016. Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the β-secretase cleaving enzyme (BACE) (verubecestat), three anti-Aβ monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1). These drugs are mainly being tested in subjects during early phases of AD or in subjects at preclinical stage of familial AD or even in asymptomatic subjects at high risk of developing AD. The hope is to intervene in the disease process when it is not too late. However, previous clinical failures with anti-Aβ drugs and the lack of fully understanding of the pathophysiological role of Aβ in the development of AD, put the new drugs at substantial risk of failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Oligomeric Aβ and ADDLs have been hypothesized to be the molecular species responsible for neuronal death and the associated cognitive decline [124,125] and represent the target of conformationspecific monoclonal antibodies that should not alter ‘physiological’ monomeric Aβ [126,127].”
BackgroundRetractedThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 1×
“Moderately positive results for interventions targeting several lifestyle factors in non-demented elderly patients suggested that, ultimately, there will be a future in which specific anti-AD drugs will be combined with lifestyle interventions [123].”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 2×
“In December 2014, Biogen announced that aducanumab would move into Phase III based on these interim data of the PRIME study suggesting target engagement and a cognitive benefit [96].”
BackgroundJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 1×
“The course of AD may be well represented by the preclinical stage, the MCI stage, and the dementia stage [29].”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Preclinical studies on differentmurine analogs of the humanizedmonoclonal antibodies showed significant reductions in brain Aβ burden and improved cognition in transgenicmousemodels of AD [77,78].”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 2×
“centric drugs for the treatment of AD such as the γ-secretase inhibitors avagacestat [97] and semagacestat [98] and the monoclonal antibody bapineuzumab [82] and the absence of marked beneficial effects for solanezumab [83] suggested that earlier intervention should be probably attempted with secondary prevention tria…”
BackgroundResultRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“The earlier MCI trials used differing definitions for MCI [2], but the advancement of trials for prodromal AD followed the proposed 2007 research criteria from the International Working Group (IWG) for New Research Criteria for the Diagnosis of AD [7], that is, diagnosing AD before dementia onset, with patients who ac…”
MethodAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 2×
“In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress, and neuroinflammation are involved in the disease pathogenesis [35], and cross talk between thesepathological pathways may synergistically drive disease progression.”
Background
Cited by
Solfrizzi, V., Custodero, C., Lozupone, M., Imbimbo, B. P., Valiani, V., Agosti, P., Schilardi, A., D’Introno, A., La Montagna, M., Calvani, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170248 · Cited by 352
Self-citationLongitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials
Staffaroni, A. M., Ljubenkov, P. A., Kornak, J., Cobigo, Y., Datta, S., Marx, G., Walters, S. M., Chiang, K., Olney, N., Elahi, F. M., et al. (2019) · Brain · doi:10.1093/brain/awy319 · Cited by 105
Gutierrez, L., Folch, A., Rojas, M., Cantero, J. L., Atienza, M., Folch, J., Camins, A., Ruiz, A., Papandreou, C., & Bulló, M. (2021) · Nutrients · doi:10.3390/nu13113728 · Cited by 105
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Self-citationRAGE Signaling in Skeletal Biology
Plotkin, L. I., Essex, A. L., & Davis, H. M. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00499-w · Cited by 54
Metadata
- Authors
- Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., Bisceglia, P., Daniele, A., Bellomo, A., Greco, A., & Logroscino, G.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-10
- Volume
- 21
- Issue
- 4
- Pages
- 377-391
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2418725963
- Cited by
- 59
- References
- 50
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. https://app.cochat.ai/papers/10.1080/14728214.2016.1241232
- The paper
- Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., Bisceglia, P., Daniele, A., Bellomo, A., Greco, A., & Logroscino, G. (2016). Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opinion on Emerging Drugs. https://doi.org/10.1080/14728214.2016.1241232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.